Clinical TrialMay 26, 2026, 08:01 AM
Esperion Presents Positive Bempedoic Acid Data at EAS Congress 2026
AI Summary
Esperion Therapeutics announced positive results from a Phase 2 study of bempedoic acid in children with familial hypercholesterolemia, showing LDL-C reduction and good tolerability. Additionally, a post hoc analysis from the CLEAR Outcomes trial identified patient factors, including female sex and higher baseline LDL-C, associated with a 30% or greater reduction in LDL-C in statin-intolerant adults. These data were presented at the European Atherosclerosis Society (EAS) Congress 2026, supporting the broad utility of bempedoic acid.
Key Highlights
- Bempedoic acid reduced LDL-C in pediatric patients aged 6-17 years by 6-25% in a Phase 2 study.
- The pediatric study showed similar drug exposure to adults and no new safety concerns.
- 42% of statin-intolerant patients in CLEAR Outcomes achieved ">="30% LDL-C reduction at 3 months.
- Enhanced LDL-C reduction was associated with female sex, higher baseline LDL-C, and concurrent ezetimibe use.
Price Impact
More from ESPR